60 DEGREES PHARMACEUTICALS, INC.
SXTPWDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Feb 2027
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
Tafenoquine
Babesiosis
Tafenoquine 100mg
Chronic Babesiosis
Tafenoquine Oral Tablet
COVID 19 Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Tafenoquine | Phase 2 | Babesiosis | - | - |
Tafenoquine 100mg | Phase 2 | Chronic Babesiosis | - | - |
Tafenoquine Oral Tablet | Phase 2 | COVID 19 Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in 60 DEGREES PHARMACEUTICALS, INC.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in 60 DEGREES PHARMACEUTICALS, INC.'s (SXTPW) pipeline across Phase 2. Its lead program is Tafenoquine (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is 60 DEGREES PHARMACEUTICALS, INC.'s next FDA catalyst?→
60 DEGREES PHARMACEUTICALS, INC.'s (SXTPW) next tracked catalyst is a Phase 2 expected February 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SXTPW biotech catalysts?→
Add SXTPW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow 60 DEGREES PHARMACEUTICALS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.